Despite the development of second-generation antiandrogens, acquired resistance to
hormone therapy remains a major challenge in treating advanced prostate cancer. We find …

Purpose: Androgen deprivation therapy (ADT), including enzalutamide, induces resistance
in prostate cancer; ADT resistance is associated with neuroendocrine differentiation (NED) …

Representative in vitro model systems that accurately model response to therapy and allow
the identification of new targets are important for improving our treatment of prostate cancer …

Purpose: In this study, we addressed the underlying mechanisms for the association
between enzalutamide (ENZ) treatment and neuroendocrine prostate cancer (NEPC), and …

The treatment of advanced prostate cancer has been transformed by novel antiandrogen
therapies such as enzalutamide. Here, we identify induction of glucocorticoid receptor (GR) …

The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC),
especially those that are consequences of treatment-induced suppression of the androgen …

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or
acquired resistance to second-generation androgen-targeting therapies and minimal …

Advanced prostate cancer invariably recurs despite androgen deprivation therapy. The
androgen receptor (AR) likely plays a key role in this progression and in the continued …

Purpose: Lineage plasticity in prostate cancer—most commonly exemplified by loss of
androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation …